Palvella Unveils Positive Phase 3 Data for QTORIN™ Rapamycin in Rare Skin Disease
Event summary
- Palvella presented three posters at Fall Clinical Dermatology 2026 highlighting Phase 3 SELVA study data for QTORIN™ rapamycin in microcystic lymphatic malformations (microcystic LMs).
- Patient, caregiver, and clinician interviews showed meaningful clinical improvements and high treatment satisfaction with QTORIN™ rapamycin.
- A maximal-use pharmacokinetic substudy demonstrated low and stable systemic rapamycin exposure over 24 hours, potentially supporting a favorable systemic exposure profile.
- A real-world claims analysis identified an estimated 154,986 U.S. patients diagnosed with disseminated superficial actinic porokeratosis (DSAP).
- Palvella completed the rolling submission of its New Drug Application (NDA) to the FDA for QTORIN™ rapamycin in August 2026.
The big picture
Palvella's positive Phase 3 data for QTORIN™ rapamycin positions the company as a key player in the rare skin disease space. The substantial patient population identified for DSAP highlights the market potential for Palvella's pipeline. The company's focus on FDA-approved therapies for rare skin diseases aligns with the growing emphasis on targeted treatments for underserved patient populations.
What we're watching
- Regulatory Approval
- Whether the FDA will approve QTORIN™ rapamycin for microcystic LMs based on the Phase 3 SELVA study data.
- Market Potential
- The pace at which Palvella can commercialize QTORIN™ rapamycin if approved, given the substantial burden of microcystic LMs and DSAP.
- Pipeline Progress
- How the Phase 2 trial of QTORIN™ pitavastatin for DSAP, anticipated to commence in Q4 2026, will progress and its potential impact on Palvella's valuation.